Statins (rosuvastatin) — The High-Potency Lipid Lowerer
Rosuvastatin is a highly potent, synthetic statin widely prescribed to lower LDL cholesterol and reduce the risk of cardiovascular disease. By mitigating atherosclerosis and systemic inflammation, it addresses one of the leading causes of age-related mortality, making it a cornerstone intervention for extending human healthspan and lifespan.
Mechanism of Action
Rosuvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for endogenous cholesterol synthesis in the liver. By decreasing hepatic cholesterol production, it upregulates low-density lipoprotein (LDL) receptors on the cell surface, enhancing the clearance of LDL-C from the bloodstream. Beyond lipid lowering, rosuvastatin exhibits pleiotropic effects, including improving endothelial function, stabilizing atherosclerotic plaques, and reducing systemic inflammation (evidenced by lowered hsCRP levels). These anti-inflammatory and plaque-stabilizing properties are thought to contribute significantly to its cardiovascular and potential longevity benefits.
Human Trial Evidence
Rosuvastatin has been extensively studied in large-scale human trials for primary and secondary cardiovascular prevention. The JUPITER trial (2008) demonstrated that 20 mg/day significantly reduced major cardiovascular events and all-cause mortality in healthy individuals with normal LDL-C but elevated high-sensitivity C-reactive protein (hsCRP). The HOPE-3 trial (2016) further confirmed that 10 mg/day reduced cardiovascular events in intermediate-risk persons without cardiovascular disease.
Dosing Protocol
5–20 mg/day is the standard starting range for primary prevention, up to 40 mg/day for high-risk patients. It is taken orally, once daily, with or without food. Because of its long half-life (~19 hours), it can be taken at any time of day. Prescription required.
Safety & Contraindications
Generally well-tolerated, but common adverse effects include myalgia (muscle pain), headache, and gastrointestinal upset. Rare but serious risks include myopathy, rhabdomyolysis, and a slight increase in the risk of incident type 2 diabetes. It is contraindicated in patients with active liver disease or unexplained persistent elevations of hepatic transaminases, and during pregnancy or breastfeeding. Caution is advised when co-administered with cyclosporine, gemfibrozil, or certain antiretroviral therapies due to increased risk of myopathy. Prescription required.